Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary L Schaer

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Cardiovascular Radiation Medicine|December 14, 2002
Clinical outcomes of patients treated with the cutting balloon and Sr-90 beta-irradiation for instent restenosisFrancis Q Almeda, David Y Chua, Sandeep Nathan, et al.
Lancet (London, England)|April 10, 2016
Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trialAmit N Patel, Timothy D Henry, Arshed A Quyyumi, et al.
JAMA|November 6, 2003
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trialGregg W Stone, Peter A McCullough, James A Tumlin, et al.
Journal of Interventional Cardiology|March 25, 2005
Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patientsJohn P Reilly, Mark A Grise, F David Fortuin, et al.
Journal of the American College of Cardiology|December 12, 2002
Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarctionSimon R Dixon, Robert J Whitbourn, Michael W Dae, et al.
Journal of the American College of Cardiology|December 5, 2009
A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarctionJoshua M Hare, Jay H Traverse, Timothy D Henry, et al.
The American Journal of Cardiology|August 14, 2003
One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patientsF David Fortuin, Peter Vale, Douglas W Losordo, et al.
European Heart Journal|January 10, 2018
Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trialsTimothy D Henry, Douglas W Losordo, Jay H Traverse, et al.
American Heart Journal|May 28, 2013
A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW studyThomas J Povsic, Candice Junge, Adel Nada, et al.
Cell Transplantation|May 7, 2016
Autologous CD34<sup>+</sup> Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI StudyTimothy D Henry, Gary L Schaer, Jay H Traverse, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Cardiovascular Radiation Medicine|December 14, 2002
Clinical outcomes of patients treated with the cutting balloon and Sr-90 beta-irradiation for instent restenosisFrancis Q Almeda, David Y Chua, Sandeep Nathan, et al.
Lancet (London, England)|April 10, 2016
Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trialAmit N Patel, Timothy D Henry, Arshed A Quyyumi, et al.
JAMA|November 6, 2003
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trialGregg W Stone, Peter A McCullough, James A Tumlin, et al.
Journal of Interventional Cardiology|March 25, 2005
Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patientsJohn P Reilly, Mark A Grise, F David Fortuin, et al.
Journal of the American College of Cardiology|December 12, 2002
Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarctionSimon R Dixon, Robert J Whitbourn, Michael W Dae, et al.
Journal of the American College of Cardiology|December 5, 2009
A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarctionJoshua M Hare, Jay H Traverse, Timothy D Henry, et al.
The American Journal of Cardiology|August 14, 2003
One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patientsF David Fortuin, Peter Vale, Douglas W Losordo, et al.
European Heart Journal|January 10, 2018
Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trialsTimothy D Henry, Douglas W Losordo, Jay H Traverse, et al.
American Heart Journal|May 28, 2013
A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW studyThomas J Povsic, Candice Junge, Adel Nada, et al.
Cell Transplantation|May 7, 2016
Autologous CD34<sup>+</sup> Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI StudyTimothy D Henry, Gary L Schaer, Jay H Traverse, et al.
Pageof 5